ArticleImmunotherapy advances2024

High-affinity T cell receptor ImmTAC® bispecific efficiently redirects T cells to kill tumor cells expressing the cancer-testis antigen PRAME.

Ana R Ribeiro et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.